BrainsWay (NASDAQ:BWAY) Shares Up 1.7% - Should You Buy?

BrainsWay Ltd. (NASDAQ:BWAY - Get Free Report) traded up 1.7% during trading on Friday . The company traded as high as $10.29 and last traded at $10.29. 37,452 shares were traded during mid-day trading, a decline of 60% from the average session volume of 94,623 shares. The stock had previously closed at $10.12.

Analyst Upgrades and Downgrades

BWAY has been the subject of a number of analyst reports. Northland Securities raised their price objective on BrainsWay from $11.00 to $12.50 and gave the stock an "outperform" rating in a research report on Thursday, October 3rd. HC Wainwright restated a "buy" rating and set a $16.00 price target on shares of BrainsWay in a report on Monday, October 21st.

BrainsWay Stock Performance

The stock has a fifty day simple moving average of $9.82 and a two-hundred day simple moving average of $7.96. The stock has a market capitalization of $171.64 million, a price-to-earnings ratio of 102.91 and a beta of 1.23.

BrainsWay (NASDAQ:BWAY - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported $0.04 EPS for the quarter, topping the consensus estimate of $0.01 by $0.03. BrainsWay had a return on equity of 3.52% and a net margin of 3.88%. The business had revenue of $10.50 million during the quarter, compared to analysts' expectations of $10.07 million. During the same quarter last year, the firm posted ($0.01) earnings per share. Research analysts forecast that BrainsWay Ltd. will post 0.06 earnings per share for the current year.

Institutional Investors Weigh In On BrainsWay

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Rhumbline Advisers raised its position in shares of BrainsWay by 10.3% during the second quarter. Rhumbline Advisers now owns 18,077 shares of the company's stock worth $110,000 after purchasing an additional 1,695 shares during the period. Perritt Capital Management Inc bought a new position in shares of BrainsWay in the second quarter valued at $121,000. Good Life Advisors LLC grew its holdings in shares of BrainsWay by 65.5% during the third quarter. Good Life Advisors LLC now owns 55,800 shares of the company's stock valued at $516,000 after buying an additional 22,080 shares during the last quarter. Finally, Acadian Asset Management LLC increased its position in shares of BrainsWay by 48.1% during the second quarter. Acadian Asset Management LLC now owns 259,787 shares of the company's stock worth $1,567,000 after acquiring an additional 84,371 shares in the last quarter. 30.11% of the stock is owned by institutional investors.

BrainsWay Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.